Literature DB >> 21297071

Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay.

N Sarita Shah1, Prashini Moodley, Palav Babaria, Salona Moodley, Melissa Ramtahal, Jessica Richardson, Scott Heysell, Xuan Li, Anthony Moll, Gerald Friedland, A Willem Sturm, Neel R Gandhi.   

Abstract

RATIONALE: Mortality is exceedingly high and rapid among patients infected with HIV and tuberculosis (TB), in part because of limited access to appropriate TB diagnostics. The microscopic observation drug-susceptibility (MODS) assay is a simple, rapid, low-cost test for TB and multidrug-resistant (MDR) TB, but data in individuals infected with HIV and in Africa are limited.
OBJECTIVES: To evaluate the MODS assay in a high-HIV-prevalence setting.
METHODS: We performed a prospective diagnostic accuracy study of consecutive adults suspected to have TB from outpatient and inpatient settings at a district hospital in rural South Africa. Sputum was tested by concentrated smear microscopy; agar (Middlebrook 7H11) and liquid (mycobacterial growth indicator tube) culture; and the MODS assay. Drug-susceptibility testing (DST) was by indirect 1% proportion method and MODS. Reference standard for Mycobacterium tuberculosis detection was growth on Middlebrook or mycobacterial growth indicator tube culture; 1% proportion was the reference standard for isoniazid and rifampin DST.
MEASUREMENTS AND MAIN RESULTS: Among 534 adults enrolled, 388 (73%) were HIV-positive, with a median CD4 count of 161 cells/mm(3) (interquartile range [IQR]: 72-307). TB was diagnosed by the reference standard culture in 113 (21%). MODS sensitivity was 85% (95% confidence interval [CI], 78-92%), and specificity was 97% (CI, 95-99%). MODS test performance did not differ by patients' HIV status (sensitivity 88% vs. 90%, specificity 97% vs. 100% for HIV-positive versus HIV-negative, respectively). For MDR-TB diagnosis (n = 11), sensitivity was 100% (one-sided CI, 68-100%) and specificity was 94% (CI, 82-98%). Median turnaround time for MDR-TB diagnosis was 7 days (IQR: 6-9) with MODS versus 70 days (IQR: 49-96) with indirect proportion method (P < 0.001).
CONCLUSIONS: Among adult TB suspects predominantly infected with HIV, MODS provided high sensitivity and specificity for rapid diagnosis of TB and MDR-TB. Given the high mortality from TB and MDR-TB and prolonged opportunity for TB transmission before diagnosis, the MODS assay warrants serious consideration for use in similar high-HIV-prevalence, resource-limited settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21297071     DOI: 10.1164/rccm.201009-1449OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  To build better tuberculosis diagnostics, look for 'biosignatures'.

Authors:  Alan Dove
Journal:  Nat Med       Date:  2015-07       Impact factor: 53.440

2.  Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Authors:  Irina Kontsevaya; Jim Werngren; Yen Holicka; Kadri Klaos; Anh Tran; Vladyslav Nikolayevskyy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-30       Impact factor: 3.267

3.  Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.

Authors:  Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

4.  Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa.

Authors:  Sheela V Shenoi; Ralph P Brooks; Russell Barbour; Frederick L Altice; Daniel Zelterman; Anthony P Moll; Iqbal Master; Theo L van der Merwe; Gerald H Friedland
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

5.  Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.

Authors:  Simon Walusimbi; Freddie Bwanga; Ayesha De Costa; Melles Haile; Moses Joloba; Sven Hoffner
Journal:  BMC Infect Dis       Date:  2013-10-30       Impact factor: 3.090

6.  Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts.

Authors:  Sheela V Shenoi; Anthony P Moll; Ralph P Brooks; Tassos Kyriakides; Laurie Andrews; Teja Kompala; Devesh Upadhya; Frederick L Altice; Francois J Eksteen; Gerald Friedland
Journal:  Open Forum Infect Dis       Date:  2017-05-04       Impact factor: 3.835

7.  Microscopic-observation drug-susceptibility assay for the diagnosis of drug-resistant tuberculosis in Harare, Zimbabwe.

Authors:  Beauty Makamure; Jesca Mhaka; Salome Makumbirofa; Reggie Mutetwa; Lucy Mupfumi; Peter Mason; John Z Metcalfe
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

8.  BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients.

Authors:  Senait Ashenafi; Getachew Aderaye; Martha Zewdie; Rubhana Raqib; Amsalu Bekele; Isabelle Magalhaes; Beede Lema; Meseret Habtamu; Rokeya Sultana Rekha; Getachew Aseffa; Markus Maeurer; Abraham Aseffa; Mattias Svensson; Jan Andersson; Susanna Brighenti
Journal:  Thorax       Date:  2012-08-24       Impact factor: 9.139

9.  A field evaluation of the Hardy TB MODS Kit™ for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis.

Authors:  Laura Martin; Jorge Coronel; Dunia Faulx; Melissa Valdez; Mutsumi Metzler; Chris Crudder; Edith Castillo; Luz Caviedes; Louis Grandjean; Mitzi Rodriguez; Jon S Friedland; Robert H Gilman; David A J Moore
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Drug resistance pattern of mycobacterial isolates in HIV and non-HIV population in South India.

Authors:  Umamaheshwari Shivaswamy; Sumana M Neelambike
Journal:  Lung India       Date:  2016 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.